Evogene’s technology is based on a powerful Computational Predictive Biology (CPB) platform coupled with a uniquely multi-disciplinary approach.
About AgPlenus Ltd.
AgPlenus, a fully owned subsidiary of Evogene, aims to discover, develop and bring to the market effective and safe agrochemical products utilizing proprietary computational predictive technologies. The Company aims to develop agrochemicals: herbicides, insecticides, fungicides and crop enhancers. AgPlenus will continue ongoing collaborations with industry leaders such as BASF and ICL. For more information, please visit www.agplenus.com
Ag-chemicals are an essential part in the farmer’s agronomical practices and are broadly used to control weeds, insects and disease. The Ag-Chemical market in 2017 was estimated at $56B, 42% of which is attributed to herbicides, 28% to insecticides and 27% to fungicides (others are 3%) and is expected to grow to over $70 billion by 20222.
Over the last few years, farmers have been faced with a significant increase in resistance to existing chemical products. This reality creates a pressing need for novel products that will secure crop yields in the coming years.
Currently, AgPlenus’ product programs are divided into:
AgPlenus combines state-of-the-art target based computational chemistry capabilities with plant genomics ‘big data’ and extensive chemical and biological know-how for the development of Ag-Chemical solutions with a novel biological mechanism.
Two proprietary computational platforms are employed Evogene’s PoinTar platform for identification of novel protein-targets in plants and the PointHit platform for target-based chemistry discovery.
The platforms’ computational predictions are then further validated in exclusive biological screening systems, including lab and greenhouse screening of weeds, crops and major insect orders, such as: Lepidoptera, Coleoptera and Hemiptera.
Lab screening is conducted at our St. Louis facility, focused on insecticidal screens of small chemical molecules with several target insects and assay types available.
Supporting these screening efforts are interdisciplinary teams of scientists from diverse backgrounds such as: chemistry, agronomy, structural biology, computer science etc.
For more information, please view AgPlenus’ company presentation: AgPlenus introduction MAYA_March_2019
2 Phillips McDougall 2016
The global seed market is valued at $37B , as of 2016, of which 53% is attributed to available biotech seeds, seeds which have been improved by gene transformation, in crops such as corn, soy and cotton. Currently available biotech seed traits capture approximately $8B and it is expected that as additional traits become available, the market may reach $14B1, thus attempting to provide a solution to improve traits such as yield, abiotic stress, disease resistance, insect control and herbicide tolerance.
As global seed companies constantly aim to reach beyond current limitations to address the world’s growing need for feed, food and fuel, Evogene forges collaborations with these global companies to discover genes and genomic elements to develop improved seed traits.
The key traits Evogene targets are:
At Evogene, we discover and develop improved seed traits, focusing on the world’s major field crops: corn, soy, wheat, rice, cotton, canola and more. Following over a decade of discovery and research into seed traits, Evogene now aims to provide a comprehensive solution of an overall package to enhance the performance of various crops.
Evogene utilizes proprietary computational platforms: ATHLETE, Gene2Product, PlaNet NG and BiomeMiner, to identify target genes and additional genomic elements, leveraging both plant and microbial gene pools including meta-genomic approaches.
Likewise, Evogene has put into place state-of-the-art validation systems for each of its key traits, to support various product development stages. Evogene’s R&D facilities in Israel and in its St. Louis site in the US, conduct discovery and validation with multi-disciplinary scientific teams to address global agricultural challenges.
Constantly evolving innovation – Genome Editing
The next frontier in genomics value capturing, gaining high traction in multiple areas in both pharma and agriculture, is Genome Editing technology.This allows the specific modification, at the molecular level, of essentially any given genome, in a highly precise and targeted manner.
Leveraging Evogene’s unique technological infrastructure and significant accumulated Big Data, allows the company the ability to precisely identify required edits in the genome. Thereby, opening a new spectrum of opportunities for seed trait improvement.
1 Source: Phillips McDougall , 2015
Yield, drought and nitrogen use efficiency in Corn, Soybean, Cotton and Canola (2004) Phase I
Yield improvement in Corn (2007) – Phase 1
Promoters for yield improvement in Wheat (2011)
Asian Soybean Rust in Soybean (2011) - Phase 1
Stalk Rot (Fusarium) in Corn (2014) – Discovery
Black Sigatoka in Banana (2007) – Phase 1
Fusarium in Wheat (2016) - Discovery
Lepidoptera in Soy (2014) - Discovery
Western Corn Root Worm in Corn (2014) – Phase I
Stinkbug (Hemiptera) in Soy (2014) – Discovery
Lepidoptera in Corn (2014) – Discovery
Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics for the treatment of immune-mediated and infectious diseases, with specific focus on Immuno-Oncology and GI related disorders.
For more information, please visit: https://www.biomicamed.com/
Canonic aims to develop next generation medical cannabis products.
Canonic’s initial activities will focus on creating improved cannabis varieties by addressing the current developmental roadblocks of yield, stability and specific metabolite composition. These development efforts will be based on the utilization of Evogene’s broadly applicable leading Computational Predictive Biology (CPB) platform, which has in the past demonstrated success in addressing similar objectives for other crops.
The current cannabis market is estimated at ~$13 billion and is expected to grow to ~$24 billion by 2025. Although the cannabis market is growing rapidly, it is well recognized that next generation products will need to address the current limitations of: (i) low metabolite yield – causing high costs for patients, (ii) low variety stability – causing inconsistent products that have become unreliable as a medical treatment and (iii) uncertainty in connecting cannabis metabolite profile to specific medical indications.
Evogene is uniquely positioned to provide a significant competitive advantage in the resolution of these development roadblocks through its CPB platform and its recognized capabilities as a leader in the area of plant genomics. Capabilities which have been developed and utilized for more than a decade through multiple collaborations.
Canonic’s current workplan focuses on three main product types, through a non-GMO approach: (i) high metabolite yield cannabis varieties (ii) stable varieties with consistent metabolite performance and (iii) cannabis varieties with a unique metabolite profile tailored to specific medical indications. The indications that the company will currently address are: post-traumatic stress disorder (PTSD), severe chronic pain and cancer.
For more information please view the company presentation: http://www.evogene.com/wp-content/uploads/2019/05/Canonic-presentation-14.4.19_Final_print-version-1.pdf
 Source: The cannabis annual report, Frontier financial group
Casterra aims to develop an ag-solution to address the growing global demand for stable castor oil supply.
In order to achieve this target, Casterra has established a unique integrated ag-solution, which includes:
The market for castor oil and its derivatives is rapidly growing and according to market publications, is expected to reach 2.3 Billion USD by 2024. Today, there are many industrial applications for castor oil, such as in the cosmetics, electronics, automotive and aerospace industries.
Lavie bio aims to improve food health, quality and agricultural sustainability through the introduction of microbiome based ag-biological products. Utilizing proprietary computational predictive technologies, Lavie bio is developing ‘next generation’ bio-stimulants and bio-pesticides and has an ongoing collaboration with industry leader Corteva for the development of corn bio-stimulants.
Ag Biologicals are products based on naturally derived sources such as plant extracts and micro-organisms (microbes, natural enemies) aimed to impact plant’s productivity. The plant extracts or naturally occurring micro-organisms, support the plant by reducing pest damage to the plant – Bio-Pesticides, or by mediating plants’ response to their environment and thereby optimizing yield potential – Bio-Stimulants.
The Ag- Biological market is an evolving agriculture segment with immense potential, estimated3 in 2015 at $3.2 billion with projected annual growth rate of approximately 11.5%. These products, which have a relatively short time to market, supplement existing solutions of improved seed traits and protective chemicals, rather than replacing them; thereby adding additional solutions to the famer’s toolbox.
In recent years, the scientific understanding of microbiome and its effect on its host’s health has taken giant steps, with the research on human microbiome also expanding into agriculture. This improvement in scientific understanding along with the development of advanced genomic sequencing and computer analysis present a unique opportunity to harness the microbiome as a source for novel products.
Evogene’s Ag-Biological activity is aimed at the discovery, optimization and development of microbiome-based, next-generation, Ag-Biological products with a variety of application methods (e.g. seed treatment, foliar, drench).
Evogene’s Ag-Biologicals activity targets the following key market segments:
We identify, optimize and develop novel Ag-Biological products through the use of Evogene’s proprietary computational predictive biology platform – MicrobeMiner, which leverages Big-Data, advanced predictive algorithms (such as Artificial Intelligence) and deep scientific understanding of the plant, pathogen and microbiome.
Our predictive computational platform is closely integrated with our end-to-end pipeline for product development, which includes sourcing & enrichment of microbes, screening & validation assays, and product development capabilities including formulation and fermentation.
For more information, visit: https://www.lavie-bio.com/
3 Source: Phillips McDougall , 2015, Dunham Trimmer 2016, Piper Jaffray, 2015